![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
P Huang and W Plunkett
Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
The action of 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) on RNA metabolism was evaluated both in whole cells and in cell-free systems. F-ara-A was converted to its 5'-triphosphate, F-ara-ATP, in cells and then incorporated into RNA as well as DNA. F-ara-A inhibited RNA synthesis in cultured cells in a concentration-dependent manner. This inhibition was mediated mainly by F-ara-ATP. Experiments using isolated nuclei demonstrated that RNA polymerases I, II, and III accounted for 24, 73, and 3% of the total RNA synthesis activity, respectively. About 88% of the total inhibition was attributed to the suppression of RNA polymerase II activity. In cultured cells, F-ara-A was preferentially incorporated into the poly(A)+ RNA fraction. Approximately 78% of the incorporated F-ara-A monophosphate residues were located at the terminal position of the RNA chain. The incorporation of F-ara-A monophosphate into mRNA resulted in premature termination of the RNA transcript and impaired its functioning as a template for protein synthesis. The inhibitory action of F-ara-A on RNA metabolism is a unique property of this compound, differing from the action of arabinosylcytosine and arabinosyladenine.
This article has been cited by other articles:
|
|
 |
|
  M. A. Moufarij, D. Sampath, M. J. Keating, and W. Plunkett Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal Blood, December 15, 2006; 108(13): 4187 - 4193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zeng, I. J. Samudio, M. Munsell, J. An, Z. Huang, E. Estey, M. Andreeff, and M. Konopleva Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias Mol. Cancer Ther., December 1, 2006; 5(12): 3113 - 3121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cervasi, M. Paiardini, S. Serafini, A. Fraternale, M. Menotta, J. Engram, B. Lawson, S. I. Staprans, G. Piedimonte, C. F. Perno, et al. Administration of Fludarabine-Loaded Autologous Red Blood Cells in Simian Immunodeficiency Virus-Infected Sooty Mangabeys Depletes pSTAT-1-Expressing Macrophages and Delays the Rebound of Viremia after Suspension of Antiretroviral Therapy. J. Virol., November 1, 2006; 80(21): 10335 - 10345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Balakrishnan, W. G. Wierda, M. J. Keating, and V. Gandhi Mechanisms of Cell Death of Chronic Lymphocytic Leukemia Lymphocytes by RNA-Directed Agent, 8-NH2-Adenosine Clin. Cancer Res., September 15, 2005; 11(18): 6745 - 6752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Burger, T. Hartmann, M. Krome, J. Rawluk, H. Tamamura, N. Fujii, T. J. Kipps, and J. A. Burger Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells Blood, September 1, 2005; 106(5): 1824 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Krett, K. M. Davies, M. Ayres, C. Ma, C. Nabhan, V. Gandhi, and S. T. Rosen 8-Amino-adenosine is a potential therapeutic agent for multiple myeloma Mol. Cancer Ther., November 1, 2004; 3(11): 1411 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhou, G. Achanta, H. Pelicano, V. Gandhi, W. Plunkett, and P. Huang Action of (E)-2'-Deoxy-2'-(fluoromethylene)cytidine on DNA Metabolism: Incorporation, Excision, and Cellular Response Mol. Pharmacol., January 1, 2002; 61(1): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mansson, T. Spasokoukotskaja, J. Sallstrom, S. Eriksson, and F. Albertioni Molecular and Biochemical Mechanisms of Fludarabine and Cladribine Resistance in a Human Promyelocytic Cell Line Cancer Res., December 1, 1999; 59(23): 5956 - 5963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Rodriguez Jr. and V. Gandhi Arabinosylguanine-induced Apoptosis of T-Lymphoblastic Cells: Incorporation into DNA Is a Necessary Step Cancer Res., October 1, 1999; 59(19): 4937 - 4943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fidias, B. A. Chabner, and M. L. Grossbard Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders Oncologist, June 1, 1996; 1(3): 125 - 139. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
